Biological Markers – Page 2

FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression

10 months ago talkbio0Tagged Biological Markers, Drug Approval, Esophageal Neoplasms, Gene Expression, inhibitors, Malignant neoplasm of stomach, Neoplasms, PD-L1, PDCD1 gene, United States Food and Drug Administration

FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval

AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches

10 months ago talkbio0Tagged AstraZeneca, Biological Markers, Immunotherapy, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma

NSCLC, biomarkers, targeted therapy, immunotherapy, AstraZeneca, lung cancer treatment

Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development

1 year ago talkbio0Tagged approvals, Biological Assay, Biological Markers, Biomarker Strategy, Clinical Development, Clinical Trial Design, Cross-Functional Collaboration, development aspects, Discover, Drug Molecule Development, End Point, Leadership, PK/ PD/, Preclinical Development, regulatory, Target, Team Building, Translational Research, Biomedical, Translational Science Leadership

Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals